sotalol has been researched along with Disease Models, Animal in 57 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF)." | 7.79 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. ( Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013) |
| "Cicletanine treatment significantly decreased the incidence of ventricular arrhythmias, increased cardiac cGMP and nitric oxide content and reduced cardiac cAMP level." | 7.78 | Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome. ( Drimba, L; Hegedüs, C; Németh, J; Peitl, B; Sári, R; Szilvássy, Z; Yin, D, 2012) |
"The effects of d,l-sotalol at therapeutic concentrations (| 7.75 | d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. ( Horng, TL; Hsieh, YC; Lin, SF; Lin, TC; Ting, CT; Wu, TJ, 2009) | |
| "This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction." | 7.75 | d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing. ( Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009) |
| "The aim of the present study was to characterize the influence of D,L-sotalol on arterial baroreflex sensitivity (BRS) which is generally considered as an estimate of vagal activity and has prognostic value in patients after myocardial infarction (MI)." | 7.71 | d,l-sotalol enhances baroreflex sensitivity in conscious rats surviving acute myocardial infarction. ( Haass, M; Krüger, C; Kübler, W; Landerer, V; Zugck, C, 2001) |
| " In adrenergically stimulated anesthetized rabbits, azimilide, clofilium, dofetilide, sematilide, and d,l-sotalol caused premature ventricular contractions and nonsustained and sustained ventricular tachyarrhythmias (NSVT and SVT) at pharmacologically equivalent intravenous doses that increased QTc intervals 20% (ED20)." | 7.70 | Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. ( Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE, 2000) |
| "The purpose of this study was to investigate, in an anesthetized pig model of low-flow myocardial ischemia, the electrophysiologic effects of the class III drug d-sotalol during myocardial ischemia." | 7.70 | Ischemia-induced action potential shortening is blunted by d-sotalol in a pig model of reversible myocardial ischemia. ( Geelen, P; Gilbert, M; O'Hara, GE; Philippon, F; Plante, S; Turgeon, J, 2000) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 7.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| " The addition of mexiletine may limit the risk of torsade de pointes because it reduced in vitro the sotalol-induced increase in action potential duration." | 7.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "This study was designed to determine the hemodynamic effects of the class III antiarrhythmic agent d-sotalol in acute ischemic heart failure at concentrations that prolong ventricular repolarization." | 7.68 | Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs. ( Kløw, NE; Mortensen, E; Refsum, H; Tande, PM, 1992) |
| "Heart failure was induced in 35 female rabbits by rapid ventricular pacing, resulting in a significant decrease of ejection fraction." | 5.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "Sotalol as a drug blocking β-receptors and potassium KCNH2 channels may interact with different substances that affect seizures." | 3.85 | Sotalol enhances the anticonvulsant action of valproate and diphenylhydantoin in the mouse maximal electroshock model. ( Banach, M; Borowicz-Reutt, KK; Popławska, M, 2017) |
| "Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF)." | 3.79 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. ( Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013) |
| "Amiodarone has a moderate slowing effect on the VT cycle length." | 3.79 | Interactions between implantable cardioverter-defibrillators and class III agents. ( Marchlinski, FE; Movsowitz, C, 1998) |
| "Cicletanine treatment significantly decreased the incidence of ventricular arrhythmias, increased cardiac cGMP and nitric oxide content and reduced cardiac cAMP level." | 3.78 | Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome. ( Drimba, L; Hegedüs, C; Németh, J; Peitl, B; Sári, R; Szilvássy, Z; Yin, D, 2012) |
"The effects of d,l-sotalol at therapeutic concentrations (| 3.75 | d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. ( Horng, TL; Hsieh, YC; Lin, SF; Lin, TC; Ting, CT; Wu, TJ, 2009) | |
| "This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction." | 3.75 | d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing. ( Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009) |
| "The aim of the present study was to characterize the influence of D,L-sotalol on arterial baroreflex sensitivity (BRS) which is generally considered as an estimate of vagal activity and has prognostic value in patients after myocardial infarction (MI)." | 3.71 | d,l-sotalol enhances baroreflex sensitivity in conscious rats surviving acute myocardial infarction. ( Haass, M; Krüger, C; Kübler, W; Landerer, V; Zugck, C, 2001) |
| "7 mM and Mg2+=1 mM), d,l-sotalol (10 and 30 microM), a class III antiarrhythmic drug, prolonged ventricular repolarization, such as QT intervals and monophasic action potential duration, and induced early after-depolarization and polymorphic ventricular tachyarrhythmia." | 3.71 | Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block. ( Ito, T; Kii, Y, 2002) |
| "The purpose of this study was to investigate, in an anesthetized pig model of low-flow myocardial ischemia, the electrophysiologic effects of the class III drug d-sotalol during myocardial ischemia." | 3.70 | Ischemia-induced action potential shortening is blunted by d-sotalol in a pig model of reversible myocardial ischemia. ( Geelen, P; Gilbert, M; O'Hara, GE; Philippon, F; Plante, S; Turgeon, J, 2000) |
| " In adrenergically stimulated anesthetized rabbits, azimilide, clofilium, dofetilide, sematilide, and d,l-sotalol caused premature ventricular contractions and nonsustained and sustained ventricular tachyarrhythmias (NSVT and SVT) at pharmacologically equivalent intravenous doses that increased QTc intervals 20% (ED20)." | 3.70 | Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. ( Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE, 2000) |
| "To evaluate the antiarrhythmic efficacy of l-sotalol and bisoprolol on inducible ventricular arrhythmias, conscious dogs with 4- to 8-day-old myocardial infarction were studied by programmed electrical stimulation." | 3.69 | Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol. ( Aidonidis, I; Brachmann, J; Hilbel, T; Kuebler, W; Rizos, I, 1994) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 3.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| " The addition of mexiletine may limit the risk of torsade de pointes because it reduced in vitro the sotalol-induced increase in action potential duration." | 3.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "This study was designed to determine the hemodynamic effects of the class III antiarrhythmic agent d-sotalol in acute ischemic heart failure at concentrations that prolong ventricular repolarization." | 3.68 | Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs. ( Kløw, NE; Mortensen, E; Refsum, H; Tande, PM, 1992) |
| "5 V, 750 ms) or programmed ventricular stimulation, creation of a small myocardial infarction, and application of antiarrhythmic drugs (ajmalin, lidocaine, sotalol)." | 3.67 | Acute induction of sustained ventricular tachycardia: a new porcine model. ( Lüderitz, B; Nitsch, J; Schmid, C, 1989) |
| "A new in vivo proarrhythmia model of drug-induced long QT syndrome was developed using the Microminipig, an incredibly small minipig established by Fuji Micra Inc." | 2.47 | Microminipig, a non-rodent experimental animal optimized for life science research: in vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of microminipig. ( Akie, Y; Itoh, K; Izumi, Y; Kaneko, N; Nakamura, Y; Saito, H; Sugiyama, A; Yamazaki, H, 2011) |
| "Antazoline is a first-generation antihistamine with antiarrhythmic properties." | 1.48 | Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. ( Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Sterneberg, M, 2018) |
| "In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits." | 1.43 | Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. ( Chiba, T; Kondo, N; Takahara, A, 2016) |
| "Heart failure was induced in 35 female rabbits by rapid ventricular pacing, resulting in a significant decrease of ejection fraction." | 1.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "Hyperkalemia is a potentially life-threatening disorder frequently occurring in hospitalized patients." | 1.34 | The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. ( Cvetanovic, I; Ke, X; Lin, C; Ranade, V; Somberg, J, 2007) |
| "Prior to polymorphic ventricular tachycardia, dispersion of APD further increased (APD70max-min: 17 +/- 3 ms; APD90max-min: 25 +/- 3 ms; p < 0." | 1.32 | Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. ( Breithardt, G; Eckardt, L; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Milberg, P; Mönnig, G, 2003) |
| "In amiodarone-treated, hypokalemic hearts, no EAD or TdP occurred." | 1.32 | Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. ( Breithardt, G; Eckardt, L; Haverkamp, W; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Wasmer, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (12.28) | 18.7374 |
| 1990's | 16 (28.07) | 18.2507 |
| 2000's | 19 (33.33) | 29.6817 |
| 2010's | 11 (19.30) | 24.3611 |
| 2020's | 4 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ornelas-Loredo, A | 1 |
| Kany, S | 1 |
| Abraham, V | 1 |
| Alzahrani, Z | 1 |
| Darbar, FA | 1 |
| Sridhar, A | 1 |
| Ahmed, M | 1 |
| Alamar, I | 1 |
| Menon, A | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Hong, L | 1 |
| Konda, S | 1 |
| Darbar, D | 1 |
| Borowicz-Reutt, KK | 2 |
| Banach, M | 2 |
| Rudkowska, M | 1 |
| Stachniuk, A | 1 |
| Alachkar, A | 1 |
| Lotfy, M | 1 |
| Adeghate, E | 1 |
| Łażewska, D | 1 |
| Kieć-Kononowicz, K | 1 |
| Sadek, B | 1 |
| Popławska, M | 1 |
| Ellermann, C | 1 |
| Sterneberg, M | 1 |
| Kochhäuser, S | 1 |
| Dechering, DG | 1 |
| Fehr, M | 2 |
| Eckardt, L | 8 |
| Frommeyer, G | 5 |
| Milberg, P | 7 |
| Uphaus, T | 1 |
| Kaiser, D | 1 |
| Kaese, S | 1 |
| Breithardt, G | 7 |
| Chiba, T | 1 |
| Kondo, N | 1 |
| Takahara, A | 1 |
| Hsieh, YC | 1 |
| Horng, TL | 1 |
| Lin, SF | 1 |
| Lin, TC | 1 |
| Ting, CT | 1 |
| Wu, TJ | 1 |
| Quan, XQ | 1 |
| Bai, R | 1 |
| Lu, JG | 1 |
| Patel, C | 1 |
| Liu, N | 1 |
| Ruan, Y | 1 |
| Chen, BD | 1 |
| Ruan, L | 1 |
| Zhang, CT | 1 |
| Sakamoto, T | 1 |
| Fujiki, A | 1 |
| Nakatani, Y | 1 |
| Sakabe, M | 1 |
| Mizumaki, K | 1 |
| Hashimoto, N | 1 |
| Inoue, H | 1 |
| Sugiyama, A | 1 |
| Nakamura, Y | 1 |
| Akie, Y | 1 |
| Saito, H | 1 |
| Izumi, Y | 1 |
| Yamazaki, H | 1 |
| Kaneko, N | 1 |
| Itoh, K | 1 |
| Witte, P | 1 |
| Stypmann, J | 3 |
| Koopmann, M | 1 |
| Lücke, M | 1 |
| Osada, N | 5 |
| Pott, C | 1 |
| Fink, M | 1 |
| Ruhe, M | 1 |
| Matsuda, T | 1 |
| Baba, A | 1 |
| Klocke, R | 1 |
| Quang, TH | 1 |
| Nikol, S | 1 |
| Müller, FU | 1 |
| Noble, D | 1 |
| Drimba, L | 1 |
| Hegedüs, C | 1 |
| Yin, D | 1 |
| Sári, R | 1 |
| Németh, J | 1 |
| Szilvássy, Z | 1 |
| Peitl, B | 1 |
| Rajamani, S | 1 |
| Grundmann, F | 1 |
| Belardinelli, L | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Franz, MR | 2 |
| Mönnig, G | 2 |
| Haverkamp, W | 2 |
| Sims, JJ | 1 |
| Miller, AW | 1 |
| Ujhelyi, MR | 1 |
| Biagetti, MO | 1 |
| Arini, PD | 1 |
| Valverde, ER | 1 |
| Bretran, GC | 1 |
| Quinteiro, RA | 1 |
| Ramtin, S | 1 |
| Wasmer, K | 1 |
| Lin, C | 1 |
| Ke, X | 1 |
| Cvetanovic, I | 1 |
| Ranade, V | 1 |
| Somberg, J | 1 |
| Tegelkamp, R | 1 |
| Schimpf, R | 1 |
| Wolpert, C | 1 |
| Borggrefe, M | 1 |
| Kaufman, ES | 1 |
| Patterson, E | 1 |
| Lynch, JJ | 2 |
| Lucchesi, BR | 2 |
| Simpson, CF | 1 |
| Boucek, RJ | 1 |
| Lu, HR | 1 |
| Remeysen, P | 1 |
| De Clerck, F | 1 |
| Verduyn, SC | 2 |
| Vos, MA | 2 |
| Gorgels, AP | 2 |
| van der Zande, J | 1 |
| Leunissen, JD | 1 |
| Wellens, HJ | 2 |
| Chézalviel-Guilbert, F | 2 |
| Davy, JM | 2 |
| Poirier, JM | 2 |
| Weissenburger, J | 3 |
| Lipcsei, GC | 1 |
| Aidonidis, I | 1 |
| Rizos, I | 1 |
| Hilbel, T | 1 |
| Kuebler, W | 1 |
| Brachmann, J | 1 |
| Bellemin-Baurreau, J | 1 |
| Poizot, A | 1 |
| Hicks, PE | 1 |
| Armstrong, JM | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 2 |
| Manning, AS | 1 |
| Bruyninckx, C | 1 |
| Ramboux, J | 1 |
| Iskos, D | 1 |
| Lurie, KG | 1 |
| Adler, SW | 1 |
| Shultz, JJ | 1 |
| Coffeen, PR | 1 |
| Mulligan, KA | 1 |
| Benditt, DG | 1 |
| Gautam, CS | 1 |
| Sharma, PL | 1 |
| Pandhi, P | 1 |
| Zabel, M | 1 |
| Hohnloser, SH | 1 |
| Behrens, S | 1 |
| Li, YG | 1 |
| Woosley, RL | 1 |
| Deplanne, V | 1 |
| Xia, YZ | 1 |
| Cheymol, G | 1 |
| Movsowitz, C | 1 |
| Marchlinski, FE | 1 |
| Wijffels, MC | 1 |
| Dorland, R | 1 |
| Allessie, MA | 1 |
| Brooks, RR | 1 |
| Drexler, AP | 1 |
| Maynard, AE | 1 |
| Al-Khalidi, H | 1 |
| Kostreva, DR | 1 |
| Shimizu, W | 1 |
| Antzelevitch, C | 3 |
| Nesterenko, VV | 1 |
| Geelen, P | 1 |
| O'Hara, GE | 1 |
| Plante, S | 1 |
| Philippon, F | 1 |
| Gilbert, M | 1 |
| Turgeon, J | 1 |
| Baczkó, I | 1 |
| El-Reyani, NE | 1 |
| Farkas, A | 1 |
| Virág, L | 1 |
| Iost, N | 1 |
| Leprán, I | 1 |
| Mátyus, P | 1 |
| Varró, A | 1 |
| Papp, JG | 1 |
| Peralta, AO | 1 |
| John, RM | 1 |
| Gaasch, WH | 1 |
| Taggart, PI | 1 |
| Martin, DT | 1 |
| Venditti, FJ | 1 |
| Krüger, C | 1 |
| Zugck, C | 1 |
| Landerer, V | 1 |
| Kübler, W | 1 |
| Haass, M | 1 |
| Akar, FG | 1 |
| Yan, GX | 1 |
| Rosenbaum, DS | 1 |
| Kii, Y | 1 |
| Ito, T | 1 |
| Perhach, JL | 1 |
| Ferguson, HC | 1 |
| McKinney, GR | 1 |
| Mortensen, E | 1 |
| Tande, PM | 1 |
| Kløw, NE | 1 |
| Refsum, H | 1 |
| Schmid, C | 1 |
| Nitsch, J | 1 |
| Lüderitz, B | 1 |
| Coskey, LA | 1 |
| Montgomery, DG | 1 |
| Khan, MI | 1 |
| Hamilton, JT | 1 |
| Manning, GW | 1 |
| Roba, J | 1 |
| Lambelin, G | 1 |
| De Schaepdryver, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Electromechanical Profiling of Arrhythmogenic Substrates and Triggers in the Long-QT Syndrome[NCT04074122] | 150 participants (Anticipated) | Observational | 2020-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for sotalol and Disease Models, Animal
| Article | Year |
|---|---|
Microminipig, a non-rodent experimental animal optimized for life science research: in vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of microminipig.
Topics: Animals; Arrhythmias, Cardiac; Atrioventricular Block; Breeding; Disease Models, Animal; Drug Evalua | 2011 |
Quinidine in short QT syndrome: an old drug for a new disease.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 2007 |
Interactions between implantable cardioverter-defibrillators and class III agents.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Dise | 1998 |
1 trial available for sotalol and Disease Models, Animal
| Article | Year |
|---|---|
Interactions between implantable cardioverter-defibrillators and class III agents.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Dise | 1998 |
54 other studies available for sotalol and Disease Models, Animal
| Article | Year |
|---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
Topics: Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diet, High-Fat; Disease Models, Animal; | 2020 |
Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.
Topics: Adrenergic beta-Antagonists; Animals; Anticonvulsants; Avoidance Learning; Brain; Disease Models, An | 2021 |
Ameliorating effects of histamine H3 receptor antagonist E177 on acute pentylenetetrazole-induced memory impairments in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; GABA Antagonists; Hippocampus; Histamine H3 Antag | 2021 |
Sotalol enhances the anticonvulsant action of valproate and diphenylhydantoin in the mouse maximal electroshock model.
Topics: Animals; Anti-Arrhythmia Agents; Anticonvulsants; Avoidance Learning; Brain; Disease Models, Animal; | 2017 |
Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Antazoline; Anti-Bacterial Agents; Arrhythm | 2018 |
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2013 |
Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.
Topics: Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Bepri | 2016 |
d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationsh | 2009 |
Pharmacological enhancement of cardiac gap junction coupling prevents arrhythmias in canine LQT2 model.
Topics: Animals; Anti-Arrhythmia Agents; Connexin 43; Disease Models, Animal; Dogs; Drug Evaluation, Preclin | 2009 |
d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing.
Topics: Action Potentials; Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agent | 2009 |
A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Female; He | 2011 |
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart; Heart | 2012 |
Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pa | 2012 |
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocar | 2012 |
Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; Elect | 2003 |
Electrical heterogeneity and arrhythmogenesis: importance of conduction velocity dispersion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, Animal; Ele | 2003 |
Role of dipolar and nondipolar components of the T wave in determining the T wave residuum in an isolated rabbit heart model.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electric Stimu | 2004 |
Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Disease Models, Animal; Drug Administr | 2004 |
The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Disease Models, Animal; Electro | 2007 |
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 2007 |
Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiograp | 1984 |
The B-aminopropionitrile-fed turkey: a model for detecting potential drug action on arterial tissue.
Topics: Aminopropionitrile; Animals; Aorta, Abdominal; Aortic Aneurysm; Aortic Diseases; Disease Models, Ani | 1983 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disea | 1995 |
The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels; Disease Models, Animal; Dogs; | 1995 |
Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Drug Inte | 1995 |
Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Chronic Disease; Disease Models, Animal; Dog | 1995 |
Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol.
Topics: Animals; Bisoprolol; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Female | 1994 |
An in vitro method for the evaluation of antiarrhythmic and antiischemic agents by using programmed electrical stimulation of rabbit heart.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Electric Stimulation; Glycine; Heart; | 1994 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Coronary Vessels; Defib | 1996 |
Differential effect of selected antiarrhythmic drugs on coronary artery ligation-induced ventricular arrhythmias on the right or left sides.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Disease Models, Animal; Dogs; Female; Ligation; M | 1995 |
Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Disease Models, Anima | 1997 |
Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Drug Therapy, C | 1998 |
Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Disease Models, Animal; Elect | 1999 |
Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, An | 2000 |
Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
Topics: Action Potentials; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agent | 2000 |
Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia.
Topics: Action Potentials; Anesthesia, General; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Di | 2000 |
Ischemia-induced action potential shortening is blunted by d-sotalol in a pig model of reversible myocardial ischemia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrophysiology; Male; | 2000 |
Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
Topics: Action Potentials; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models | 2000 |
The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Disease Models, Anima | 2000 |
d,l-sotalol enhances baroreflex sensitivity in conscious rats surviving acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Baroreflex; Blood Pressur | 2001 |
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome.
Topics: Action Potentials; Animals; Body Surface Potential Mapping; Disease Models, Animal; Dogs; Electric S | 2002 |
Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzamides; Cisapride; Dimethyl Sulfoxide; Disea | 2002 |
Evaluation of antihypertensive agents in the stress-induced hypertensive rat.
Topics: Animals; Antihypertensive Agents; Chlorisondamine; Disease Models, Animal; Drug Evaluation, Preclini | 1975 |
Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs.
Topics: Acute Disease; Animals; Coronary Disease; Diastole; Disease Models, Animal; Dogs; Dose-Response Rela | 1992 |
Acute induction of sustained ventricular tachycardia: a new porcine model.
Topics: Animals; Disease Models, Animal; Electric Stimulation; Electrocardiography; Heart; Heart Ventricles; | 1989 |
Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Death, Sudden; Diseas | 1985 |
Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Animals; Coronary Disease; Disease Models | 1972 |
Antihypertensive activity of four blocking agents in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Antihypertensive Agents; Blood Pressure; Clonidine | 1972 |